1
|
Schmoele-Thoma B, Zareba AM, Jiang Q, Maddur MS, Danaf R, Mann A, Eze K, Fok-Seang J, Kabir G, Catchpole A, Scott DA, Gurtman AC, Jansen KU, Gruber WC, Dormitzer PR, Swanson KA. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study. N Engl J Med 2022; 386:2377-2386. [PMID: 35731653 DOI: 10.1056/nejmoa2116154] [Citation(s) in RCA: 43] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND Although human respiratory syncytial virus (RSV) is an important cause of illness and death in older adults, no RSV vaccine has been licensed. METHODS In a phase 2a study, we randomly assigned healthy adults (18 to 50 years of age), in a 1:1 ratio, to receive a single intramuscular injection of either bivalent prefusion F (RSVpreF) vaccine or placebo. Approximately 28 days after injection, participants were inoculated intranasally with the RSV A Memphis 37b challenge virus and observed for 12 days. The per-protocol prespecified primary end points were the following: reverse-transcriptase-quantitative polymerase-chain-reaction (RT-qPCR)-confirmed detectable RSV infection on at least 2 consecutive days with at least one clinical symptom of any grade from two categories or at least one grade 2 symptom from any category, the total symptom score from day 1 to discharge, and the area under the curve (AUC) for the RSV viral load in nasal-wash samples measured by means of RT-qPCR from day 2 after challenge to discharge. In addition, we assessed immunogenicity and safety. RESULTS After participants were inoculated with the challenge virus, vaccine efficacy of 86.7% (95% CI, 53.8 to 96.5) was observed for symptomatic RSV infection confirmed by any detectable viral RNA on at least 2 consecutive days. The median AUC for the RSV viral load (hours × log10 copies per milliliter) as measured by RT-qPCR assay was 0.0 (interquartile range, 0.0 to 19.0) in the vaccine group and 96.7 (interquartile range, 0.0 to 675.3) in the placebo group. The geometric mean factor increase from baseline in RSV A-neutralizing titers 28 days after injection was 20.5 (95% CI, 16.6 to 25.3) in the vaccine group and 1.1 (95% CI, 0.9 to 1.3) in the placebo group. More local injection-site pain was noted in the vaccine group than in the placebo group. No serious adverse events were observed in either group. CONCLUSIONS RSVpreF vaccine was effective against symptomatic RSV infection and viral shedding. No evident safety concerns were identified. These findings provide support for further evaluation of RSVpreF vaccine in a phase 3 efficacy study. (Funded by Pfizer; EudraCT number, 2020-003887-21; ClinicalTrials.gov number, NCT04785612.).
Collapse
Affiliation(s)
- Beate Schmoele-Thoma
- From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.)
| | - Agnieszka M Zareba
- From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.)
| | - Qin Jiang
- From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.)
| | - Mohan S Maddur
- From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.)
| | - Rana Danaf
- From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.)
| | - Alex Mann
- From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.)
| | - Kingsley Eze
- From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.)
| | - Juin Fok-Seang
- From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.)
| | - Golam Kabir
- From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.)
| | - Andrew Catchpole
- From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.)
| | - Daniel A Scott
- From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.)
| | - Alejandra C Gurtman
- From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.)
| | - Kathrin U Jansen
- From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.)
| | - William C Gruber
- From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.)
| | - Philip R Dormitzer
- From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.)
| | - Kena A Swanson
- From Vaccine Research and Development, Pfizer Pharma, Berlin (B.S.-T.); Vaccine Research and Development, Pfizer, Collegeville, PA (A.M.Z., Q.J., D.A.S.); Vaccine Research and Development, Pfizer, Pearl River, NY (M.S.M., A.C.G., K.U.J., W.C.G., P.R.D., K.A.S.); and hVIVO, London (R.D., A.M., K.E., J.F.-S., G.K., A.C.)
| |
Collapse
|
2
|
Baber J, Arya M, Moodley Y, Jaques A, Jiang Q, Swanson KA, Cooper D, Maddur MS, Loschko J, Gurtman A, Jansen KU, Gruber WC, Dormitzer PR, Schmoele-Thoma B. A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults. J Infect Dis 2022; 226:2054-2063. [PMID: 35543281 PMCID: PMC9749002 DOI: 10.1093/infdis/jiac189] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Revised: 04/29/2022] [Accepted: 05/09/2022] [Indexed: 01/04/2023] Open
Abstract
BACKGROUND Respiratory syncytial virus (RSV) is an important cause of disease in older adults. We evaluated the safety and immunogenicity of a stabilized RSV prefusion F subunit (RSVpreF) vaccine candidate with/without adjuvant in adults aged 65-85 years. METHODS Primary cohort participants were equally randomized to 1 of 7 RSVpreF formulations: 60 µg with either Al(OH)3 or CpG/Al(OH)3, 120 µg with either Al(OH)3 or CpG/Al(OH)3, 240 µg with either Al(OH)3 or CpG/Al(OH)3, 240 µg unadjuvanted, or placebo, administered concomitantly with high-dose seasonal inactivated influenza vaccine (SIIV). Participants in the month 0,2 cohort were randomized to RSVpreF 240 µg with CpG/Al(OH)3 or placebo, administered at months 0 and 2. RESULTS All RSVpreF vaccine candidates elicited robust and persistent serum neutralizing responses when administered alone or with SIIV. There was no notable difference in neutralizing response between the formulations, including those containing CpG. In the month 0,2 cohort, there was no booster effect of dose 2. SIIV responses were similar or slightly lower with concomitant administration of RSVpreF. Most systemic and local reactions were mild and more frequent after RSVpreF than placebo. CONCLUSIONS RSVpreF formulations were well tolerated and elicited robust neutralizing responses in older adults; however, CpG/Al(OH)3 did not further enhance responses. Clinical Trials Registration. NCT03572062.
Collapse
Affiliation(s)
- James Baber
- Correspondence: James Baber, MBChB, MPH, Pfizer Vaccine Clinical Research and Development, Level 15-18, 151 Clarence Street, Sydney 2000, Australia ()
| | - Mark Arya
- Australian Clinical Research Network, Maroubra, Australia
| | - Yuben Moodley
- School of Medicine, University of Western Australia, Perth, WA, Australia
| | - Anna Jaques
- Vaccine Clinical Research, Pfizer Inc, Sydney, Australia
| | - Qin Jiang
- Vaccine Research and Development, Pfizer Inc, Pearl River, New York, USA
| | - Kena A Swanson
- Vaccine Research and Development, Pfizer Inc, Pearl River, New York, USA
| | - David Cooper
- Vaccine Research and Development, Pfizer Inc, Pearl River, New York, USA
| | - Mohan S Maddur
- Vaccine Research and Development, Pfizer Inc, Pearl River, New York, USA
| | - Jakob Loschko
- Vaccine Research and Development, Pfizer Inc, Pearl River, New York, USA
| | - Alejandra Gurtman
- Vaccine Research and Development, Pfizer Inc, Pearl River, New York, USA
| | - Kathrin U Jansen
- Vaccine Research and Development, Pfizer Inc, Pearl River, New York, USA
| | - William C Gruber
- Vaccine Research and Development, Pfizer Inc, Pearl River, New York, USA
| | - Philip R Dormitzer
- Vaccine Research and Development, Pfizer Inc, Pearl River, New York, USA
| | | |
Collapse
|
3
|
Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, Kranz LM, Walzer KC, Hein S, Güler A, Loschko J, Maddur MS, Ota-Setlik A, Tompkins K, Cole J, Lui BG, Ziegenhals T, Plaschke A, Eisel D, Dany SC, Fesser S, Erbar S, Bates F, Schneider D, Jesionek B, Sänger B, Wallisch AK, Feuchter Y, Junginger H, Krumm SA, Heinen AP, Adams-Quack P, Schlereth J, Schille S, Kröner C, de la Caridad Güimil Garcia R, Hiller T, Fischer L, Sellers RS, Choudhary S, Gonzalez O, Vascotto F, Gutman MR, Fontenot JA, Hall-Ursone S, Brasky K, Griffor MC, Han S, Su AAH, Lees JA, Nedoma NL, Mashalidis EH, Sahasrabudhe PV, Tan CY, Pavliakova D, Singh G, Fontes-Garfias C, Pride M, Scully IL, Ciolino T, Obregon J, Gazi M, Carrion R, Alfson KJ, Kalina WV, Kaushal D, Shi PY, Klamp T, Rosenbaum C, Kuhn AN, Türeci Ö, Dormitzer PR, Jansen KU, Sahin U. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 2021; 592:283-289. [PMID: 33524990 DOI: 10.1038/s41586-021-03275-y] [Citation(s) in RCA: 400] [Impact Index Per Article: 133.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Accepted: 01/20/2021] [Indexed: 01/16/2023]
Abstract
A safe and effective vaccine against COVID-19 is urgently needed in quantities that are sufficient to immunize large populations. Here we report the preclinical development of two vaccine candidates (BNT162b1 and BNT162b2) that contain nucleoside-modified messenger RNA that encodes immunogens derived from the spike glycoprotein (S) of SARS-CoV-2, formulated in lipid nanoparticles. BNT162b1 encodes a soluble, secreted trimerized receptor-binding domain (known as the RBD-foldon). BNT162b2 encodes the full-length transmembrane S glycoprotein, locked in its prefusion conformation by the substitution of two residues with proline (S(K986P/V987P); hereafter, S(P2) (also known as P2 S)). The flexibly tethered RBDs of the RBD-foldon bind to human ACE2 with high avidity. Approximately 20% of the S(P2) trimers are in the two-RBD 'down', one-RBD 'up' state. In mice, one intramuscular dose of either candidate vaccine elicits a dose-dependent antibody response with high virus-entry inhibition titres and strong T-helper-1 CD4+ and IFNγ+CD8+ T cell responses. Prime-boost vaccination of rhesus macaques (Macaca mulatta) with the BNT162b candidates elicits SARS-CoV-2-neutralizing geometric mean titres that are 8.2-18.2× that of a panel of SARS-CoV-2-convalescent human sera. The vaccine candidates protect macaques against challenge with SARS-CoV-2; in particular, BNT162b2 protects the lower respiratory tract against the presence of viral RNA and shows no evidence of disease enhancement. Both candidates are being evaluated in phase I trials in Germany and the USA1-3, and BNT162b2 is being evaluated in an ongoing global phase II/III trial (NCT04380701 and NCT04368728).
Collapse
MESH Headings
- Aging/immunology
- Animals
- Antibodies, Neutralizing/immunology
- Antibodies, Viral/immunology
- Antigens, Viral/chemistry
- Antigens, Viral/genetics
- Antigens, Viral/immunology
- BNT162 Vaccine
- COVID-19/blood
- COVID-19/immunology
- COVID-19/prevention & control
- COVID-19/therapy
- COVID-19/virology
- COVID-19 Vaccines/administration & dosage
- COVID-19 Vaccines/chemistry
- COVID-19 Vaccines/genetics
- COVID-19 Vaccines/immunology
- Cell Line
- Clinical Trials as Topic
- Disease Models, Animal
- Female
- Humans
- Immunization, Passive
- Internationality
- Macaca mulatta/immunology
- Macaca mulatta/virology
- Male
- Mice
- Mice, Inbred BALB C
- Models, Molecular
- Protein Multimerization
- RNA, Viral/analysis
- Respiratory System/immunology
- Respiratory System/virology
- SARS-CoV-2/chemistry
- SARS-CoV-2/genetics
- SARS-CoV-2/immunology
- Solubility
- Spike Glycoprotein, Coronavirus/chemistry
- Spike Glycoprotein, Coronavirus/genetics
- Spike Glycoprotein, Coronavirus/immunology
- T-Lymphocytes/immunology
- Vaccination
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/chemistry
- Vaccines, Synthetic/genetics
- Vaccines, Synthetic/immunology
- COVID-19 Serotherapy
- mRNA Vaccines
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Journey Cole
- Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Olga Gonzalez
- Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA
| | - Fulvia Vascotto
- TRON-Translational Oncology at the University Medical Centre of the Johannes Gutenberg University, Mainz, Germany
| | - Matthew R Gutman
- VCA SouthPaws Veterinary Specialists and Emergency Center, Fairfax, VA, USA
| | | | - Shannan Hall-Ursone
- Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA
| | - Kathleen Brasky
- Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Michal Gazi
- Texas Biomedical Research Institute, San Antonio, TX, USA
| | - Ricardo Carrion
- Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA
| | | | | | - Deepak Kaushal
- Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, USA
| | - Pei-Yong Shi
- University of Texas Medical Branch, Galveston, TX, USA
| | | | | | | | | | | | | | - Ugur Sahin
- BioNTech, Mainz, Germany.
- TRON-Translational Oncology at the University Medical Centre of the Johannes Gutenberg University, Mainz, Germany.
| |
Collapse
|
4
|
Hagan T, Cortese M, Rouphael N, Boudreau C, Linde C, Maddur MS, Das J, Wang H, Guthmiller J, Zheng NY, Huang M, Uphadhyay AA, Gardinassi L, Petitdemange C, McCullough MP, Johnson SJ, Gill K, Cervasi B, Zou J, Bretin A, Hahn M, Gewirtz AT, Bosinger SE, Wilson PC, Li S, Alter G, Khurana S, Golding H, Pulendran B. Antibiotics-Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans. Cell 2020; 178:1313-1328.e13. [PMID: 31491384 DOI: 10.1016/j.cell.2019.08.010] [Citation(s) in RCA: 331] [Impact Index Per Article: 82.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Revised: 06/21/2019] [Accepted: 08/06/2019] [Indexed: 12/16/2022]
Abstract
Emerging evidence indicates a central role for the microbiome in immunity. However, causal evidence in humans is sparse. Here, we administered broad-spectrum antibiotics to healthy adults prior and subsequent to seasonal influenza vaccination. Despite a 10,000-fold reduction in gut bacterial load and long-lasting diminution in bacterial diversity, antibody responses were not significantly affected. However, in a second trial of subjects with low pre-existing antibody titers, there was significant impairment in H1N1-specific neutralization and binding IgG1 and IgA responses. In addition, in both studies antibiotics treatment resulted in (1) enhanced inflammatory signatures (including AP-1/NR4A expression), observed previously in the elderly, and increased dendritic cell activation; (2) divergent metabolic trajectories, with a 1,000-fold reduction in serum secondary bile acids, which was highly correlated with AP-1/NR4A signaling and inflammasome activation. Multi-omics integration revealed significant associations between bacterial species and metabolic phenotypes, highlighting a key role for the microbiome in modulating human immunity.
Collapse
Affiliation(s)
- Thomas Hagan
- Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305, USA
| | - Mario Cortese
- Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305, USA
| | - Nadine Rouphael
- Hope Clinic of the Emory Vaccine Center, Decatur, GA 30030, USA
| | - Carolyn Boudreau
- Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA
| | - Caitlin Linde
- Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA
| | - Mohan S Maddur
- Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, GA 30329, USA
| | - Jishnu Das
- Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA
| | - Hong Wang
- Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, GA 30329, USA
| | - Jenna Guthmiller
- Department of Medicine, Section of Rheumatology, Knapp Center for Lupus and Immunology, University of Chicago, Chicago, IL 60637, USA
| | - Nai-Ying Zheng
- Department of Medicine, Section of Rheumatology, Knapp Center for Lupus and Immunology, University of Chicago, Chicago, IL 60637, USA
| | - Min Huang
- Department of Medicine, Section of Rheumatology, Knapp Center for Lupus and Immunology, University of Chicago, Chicago, IL 60637, USA
| | - Amit A Uphadhyay
- Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, GA 30329, USA
| | - Luiz Gardinassi
- Department of Medicine, Emory University, Atlanta, GA 30303, USA
| | - Caroline Petitdemange
- Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, GA 30329, USA
| | | | - Sara Jo Johnson
- Hope Clinic of the Emory Vaccine Center, Decatur, GA 30030, USA
| | - Kiran Gill
- Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, GA 30329, USA
| | - Barbara Cervasi
- Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, GA 30329, USA
| | - Jun Zou
- Center for Inflammation, Immunity, and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA
| | - Alexis Bretin
- Center for Inflammation, Immunity, and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA
| | - Megan Hahn
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Andrew T Gewirtz
- Center for Inflammation, Immunity, and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA
| | - Steve E Bosinger
- Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, GA 30329, USA
| | - Patrick C Wilson
- Department of Medicine, Section of Rheumatology, Knapp Center for Lupus and Immunology, University of Chicago, Chicago, IL 60637, USA
| | - Shuzhao Li
- Department of Medicine, Emory University, Atlanta, GA 30303, USA
| | - Galit Alter
- Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA
| | - Surender Khurana
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Hana Golding
- Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA
| | - Bali Pulendran
- Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University, Stanford, CA 94305, USA; Department of Pathology, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA; Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford University, Stanford, CA 94305, USA.
| |
Collapse
|
5
|
Sharma M, Das M, Stephen-Victor E, Galeotti C, Karnam A, Maddur MS, Bruneval P, Kaveri SV, Bayry J. Regulatory T cells induce activation rather than suppression of human basophils. Sci Immunol 2019; 3:3/23/eaan0829. [PMID: 29802207 DOI: 10.1126/sciimmunol.aan0829] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Revised: 11/29/2017] [Accepted: 03/29/2018] [Indexed: 12/31/2022]
Abstract
Basophils are a rare granulocyte population that has been associated with allergic and inflammatory responses. It is essential to understand the regulatory mechanisms by which basophils are kept in check, considering the impact of dysregulated basophil function on immune responses under different pathological conditions. Among immunoregulatory cells, CD4+CD25+FoxP3+ regulatory T cells (Tregs) are the key players that maintain immune tolerance. The mechanisms by which Tregs regulate and suppress diverse immune cell subsets have been studied extensively, but the impact of Tregs on basophil functions is not well understood. We report that human basophils are refractory to Treg-mediated suppression and found that Tregs stimulate resting basophils to induce the expression of activation markers including CD69, CD203c, and CD13 and the release of basophil cytokines including IL-13, IL-8, and IL-4. Mechanistically, Tregs could induce human basophil activation via IL-3 and STAT5 activation, whereas cellular contact was dispensable. Inhibition of either IL-3-IL-3 receptor interactions or STAT5 phosphorylation abrogated Treg-mediated activation of basophils. These results provide evidence of direct positive effects that human Tregs have on basophil activation and reveal a previously unrecognized feature of this cell subset well known for immunosuppressive functions.
Collapse
Affiliation(s)
- Meenu Sharma
- Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris F-75006, France.,Université de Technologie de Compiègne, Compiègne F-60205, France
| | - Mrinmoy Das
- Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris F-75006, France
| | - Emmanuel Stephen-Victor
- Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris F-75006, France
| | - Caroline Galeotti
- Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris F-75006, France
| | - Anupama Karnam
- Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris F-75006, France
| | - Mohan S Maddur
- Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris F-75006, France
| | - Patrick Bruneval
- Service d'anatomie pathologique, Hôpital Européen Georges Pompidou, Paris F-75015, France
| | - Srini V Kaveri
- Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris F-75006, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris F-75006, France
| | - Jagadeesh Bayry
- Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris F-75006, France. .,Université Paris Descartes, Sorbonne Paris Cité, Paris F-75006, France
| |
Collapse
|
6
|
Galeotti C, Stephen-Victor E, Karnam A, Das M, Gilardin L, Maddur MS, Wymann S, Vonarburg C, Chevailler A, Dimitrov JD, Benveniste O, Bruhns P, Kaveri SV, Bayry J. Intravenous immunoglobulin induces IL-4 in human basophils by signaling through surface-bound IgE. J Allergy Clin Immunol 2018; 144:524-535.e8. [PMID: 30529242 DOI: 10.1016/j.jaci.2018.10.064] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2018] [Revised: 10/01/2018] [Accepted: 10/24/2018] [Indexed: 10/27/2022]
Abstract
BACKGROUND Therapeutic normal IgG or intravenous immunoglobulin (IVIG) exerts anti-inflammatory effects through several mutually nonexclusive mechanisms. Recent data in mouse models of autoimmune disease suggest that IVIG induces IL-4 in basophils by enhancing IL-33 in SIGN-related 1-positive innate cells. However, translational insight on these data is lacking. OBJECTIVE We sought to investigate the effect of IVIG on human basophil functions. METHODS Isolated circulating basophils from healthy donors were cultured in the presence of IL-3, IL-33, GM-CSF, thymic stromal lymphopoietin, or IL-25. The effect of IVIG and F(ab')2 and Fc IVIG fragments was examined based on expression of various surface molecules, phosphorylation of spleen tyrosine kinase, induction of cytokines, and histamine release. Basophil phenotypes were also analyzed from IVIG-treated patients with myopathy. Approaches, such as depletion of anti-IgE reactivity from IVIG, blocking antibodies, or inhibitors, were used to investigate the mechanisms. RESULTS We report that IVIG directly induces activation of IL-3-primed human basophils, but IL-33 and other cytokines were dispensable for this effect. Activation of basophils by IVIG led to enhanced expression of CD69 and secretion of IL-4, IL-6, and IL-8. IVIG-treated patients with myopathy displayed enhanced expression of CD69 on basophils. The spleen tyrosine kinase pathway is implicated in these functions of IVIG and were mediated by F(ab')2 fragments. Mechanistically, IVIG induced IL-4 in human basophils by interacting with basophil surface-bound IgE but independent of FcγRII, type II Fc receptors, C-type lectin receptors, and sialic acid-binding immunoglobulin-like lectins. CONCLUSION These results uncovered a pathway of promoting the TH2 response by IVIG through direct interaction of IgG with human basophils.
Collapse
Affiliation(s)
- Caroline Galeotti
- Institut National de la Santé et de la Recherche Médicale and Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris, France; Service de Rhumatologie Pédiatrique, Centre de Référence des Maladies Auto-Inflammatoires rares et des Amyloses, CHU de Bicêtre, Le Kremlin Bicêtre, France
| | - Emmanuel Stephen-Victor
- Institut National de la Santé et de la Recherche Médicale and Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris, France
| | - Anupama Karnam
- Institut National de la Santé et de la Recherche Médicale and Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris, France
| | - Mrinmoy Das
- Institut National de la Santé et de la Recherche Médicale and Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris, France
| | - Laurent Gilardin
- Institut National de la Santé et de la Recherche Médicale and Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris, France; Département de Médecine Interne et Immunologie Clinique, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France
| | - Mohan S Maddur
- Institut National de la Santé et de la Recherche Médicale and Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Sandra Wymann
- Research Department, CSL Behring AG, Bern, Switzerland
| | | | - Alain Chevailler
- Laboratoire d'Immunologie et d'Allergologie, CHU d'Angers, Université d'Angers, INSERM Unité 1232, LabEx IGO "Immuno-Graft-Onco", Angers, France
| | - Jordan D Dimitrov
- Institut National de la Santé et de la Recherche Médicale and Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Olivier Benveniste
- Département de Médecine Interne et Immunologie Clinique, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France; Sorbonne Université, Institut National de la Santé et de la Recherche Médicale Unité 974, Paris, France
| | - Pierre Bruhns
- Institut Pasteur, Department of Immunology, Unit of Antibodies in Therapy and Pathology, Paris, France; INSERM, U1222, Paris, France
| | - Srini V Kaveri
- Institut National de la Santé et de la Recherche Médicale and Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Jagadeesh Bayry
- Institut National de la Santé et de la Recherche Médicale and Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Sorbonne Université, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
| |
Collapse
|
7
|
Maddur MS, Kaveri SV, Bayry J. Circulating Normal IgG as Stimulator of Regulatory T Cells: Lessons from Intravenous Immunoglobulin. Trends Immunol 2017; 38:789-792. [PMID: 28916232 DOI: 10.1016/j.it.2017.08.008] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2017] [Revised: 08/07/2017] [Accepted: 08/25/2017] [Indexed: 01/09/2023]
Abstract
Intravenous immunoglobulin (IVIG), a pooled normal IgG formulation prepared from thousands of healthy donors' plasma, is extensively used for the immunotherapy of autoimmune and inflammatory disorders. Recent reports demonstrate that IVIG exerts anti-inflammatory actions by stimulating the activation and expansion of regulatory T (Treg) cells by multiple mechanisms via antigen-presenting cells (APCs).
Collapse
Affiliation(s)
- Mohan S Maddur
- Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris, F-75006, France; Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Paris, F-75006, France; Sorbonne Universités, UPMC University Paris 06, UMR S 1138, Paris, F-75006, France; Present Address: Pfizer Inc, Pearl River, NY, USA
| | - Srini V Kaveri
- Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris, F-75006, France; Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Paris, F-75006, France; Sorbonne Universités, UPMC University Paris 06, UMR S 1138, Paris, F-75006, France; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris, F-75006, France
| | - Jagadeesh Bayry
- Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris, F-75006, France; Centre de Recherche des Cordeliers, Equipe-Immunopathologie et Immunointervention Thérapeutique, Paris, F-75006, France; Sorbonne Universités, UPMC University Paris 06, UMR S 1138, Paris, F-75006, France; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris, F-75006, France.
| |
Collapse
|
8
|
Li S, Sullivan NL, Rouphael N, Yu T, Banton S, Maddur MS, McCausland M, Chiu C, Canniff J, Dubey S, Liu K, Tran V, Hagan T, Duraisingham S, Wieland A, Mehta AK, Whitaker JA, Subramaniam S, Jones DP, Sette A, Vora K, Weinberg A, Mulligan MJ, Nakaya HI, Levin M, Ahmed R, Pulendran B. Metabolic Phenotypes of Response to Vaccination in Humans. Cell 2017; 169:862-877.e17. [PMID: 28502771 DOI: 10.1016/j.cell.2017.04.026] [Citation(s) in RCA: 181] [Impact Index Per Article: 25.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2016] [Revised: 02/07/2017] [Accepted: 04/18/2017] [Indexed: 12/22/2022]
Abstract
Herpes zoster (shingles) causes significant morbidity in immune compromised hosts and older adults. Whereas a vaccine is available for prevention of shingles, its efficacy declines with age. To help to understand the mechanisms driving vaccinal responses, we constructed a multiscale, multifactorial response network (MMRN) of immunity in healthy young and older adults immunized with the live attenuated shingles vaccine Zostavax. Vaccination induces robust antigen-specific antibody, plasmablasts, and CD4+ T cells yet limited CD8+ T cell and antiviral responses. The MMRN reveals striking associations between orthogonal datasets, such as transcriptomic and metabolomics signatures, cell populations, and cytokine levels, and identifies immune and metabolic correlates of vaccine immunity. Networks associated with inositol phosphate, glycerophospholipids, and sterol metabolism are tightly coupled with immunity. Critically, the sterol regulatory binding protein 1 and its targets are key integrators of antibody and T follicular cell responses. Our approach is broadly applicable to study human immunity and can help to identify predictors of efficacy as well as mechanisms controlling immunity to vaccination.
Collapse
Affiliation(s)
- Shuzhao Li
- Department of Medicine, School of Medicine, Emory University, Atlanta, GA 30303, USA
| | - Nicole L Sullivan
- Emory Vaccine Center, Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, GA 30329, USA
| | - Nadine Rouphael
- Department of Medicine, School of Medicine, Emory University, Atlanta, GA 30303, USA; Hope Clinic of the Emory Vaccine Center, Decatur, GA 30030, USA
| | - Tianwei Yu
- Department of Bioinformatics and Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA 30030, USA
| | - Sophia Banton
- Department of Medicine, School of Medicine, Emory University, Atlanta, GA 30303, USA
| | - Mohan S Maddur
- Emory Vaccine Center, Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, GA 30329, USA
| | - Megan McCausland
- Emory Vaccine Center, Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, GA 30329, USA
| | - Christopher Chiu
- Emory Vaccine Center, Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, GA 30329, USA
| | - Jennifer Canniff
- University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Sheri Dubey
- Department of Infectious Diseases and Vaccines-West Point, PA, Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | - Ken Liu
- Department of Medicine, School of Medicine, Emory University, Atlanta, GA 30303, USA
| | - ViLinh Tran
- Department of Medicine, School of Medicine, Emory University, Atlanta, GA 30303, USA
| | - Thomas Hagan
- Emory Vaccine Center, Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, GA 30329, USA
| | - Sai Duraisingham
- Emory Vaccine Center, Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, GA 30329, USA
| | - Andreas Wieland
- Emory Vaccine Center, Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, GA 30329, USA
| | - Aneesh K Mehta
- Department of Medicine, School of Medicine, Emory University, Atlanta, GA 30303, USA
| | - Jennifer A Whitaker
- Department of Medicine, School of Medicine, Emory University, Atlanta, GA 30303, USA
| | - Shankar Subramaniam
- Department of Bioengineering, Department of Chemistry and Biochemistry, Department of Nanoengineering, Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093, USA
| | - Dean P Jones
- Department of Medicine, School of Medicine, Emory University, Atlanta, GA 30303, USA
| | - Alessandro Sette
- Division of Vaccine Discovery, La Jolla Institute of Immunology, La Jolla, CA 92037, USA
| | - Kalpit Vora
- Department of Infectious Diseases and Vaccines-West Point, PA, Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | - Adriana Weinberg
- University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Mark J Mulligan
- Department of Medicine, School of Medicine, Emory University, Atlanta, GA 30303, USA; Hope Clinic of the Emory Vaccine Center, Decatur, GA 30030, USA
| | - Helder I Nakaya
- School of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508, Brazil; Department of Pathology, School of Medicine, Emory University, Atlanta, GA 30329, USA
| | - Myron Levin
- University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
| | - Rafi Ahmed
- Emory Vaccine Center, Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, GA 30329, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA
| | - Bali Pulendran
- Emory Vaccine Center, Yerkes National Primate Research Center, 954 Gatewood Road, Atlanta, GA 30329, USA; Department of Pathology, School of Medicine, Emory University, Atlanta, GA 30329, USA.
| |
Collapse
|
9
|
Maddur MS, Stephen-Victor E, Das M, Prakhar P, Sharma VK, Singh V, Rabin M, Trinath J, Balaji KN, Bolgert F, Vallat JM, Magy L, Kaveri SV, Bayry J. Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy. J Neuroinflammation 2017; 14:58. [PMID: 28320438 PMCID: PMC5360043 DOI: 10.1186/s12974-017-0818-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Accepted: 02/18/2017] [Indexed: 02/08/2023] Open
Abstract
Background Intravenous immunoglobulin (IVIG) is a polyspecific pooled immunoglobulin G preparation and one of the commonly used therapeutics for autoimmune diseases including those of neurological origin. A recent report in murine model proposed that IVIG expands regulatory T (Treg) cells via induction of interleukin 33 (IL-33). However, translational insight on these observations is lacking. Methods Ten newly diagnosed Guillain-Barré syndrome (GBS) patients were treated with IVIG at the rate of 0.4 g/kg for three to five consecutive days. Clinical evaluation for muscular weakness was performed by Medical Research Council (MRC) and modified Rankin scoring (MRS) system. Heparinized blood samples were collected before and 1, 2, and 4–5 weeks post-IVIG therapy. Peripheral blood mononuclear cells were stained for surface CD4 and intracellular Foxp3, IFN-γ, and tumor necrosis factor alpha (TNF-α) and were analyzed by flow cytometry. IL-33 and prostaglandin E2 in the plasma were measured by ELISA. Results The fold changes in plasma IL-33 at week 1 showed no correlation with the MRC and MRS scores at weeks 1, 2, and ≥4 post-IVIG therapy. Clinical recovery following IVIG therapy appears to be associated with Treg cell response. Contrary to murine study, there was no association between the fold changes in IL-33 at week 1 and Treg cell frequency at weeks 1, 2, and ≥4 post-IVIG therapy. Treg cell-mediated clinical response to IVIG therapy in GBS patients was associated with reciprocal regulation of effector T cells-expressing TNF-α. Conclusion Treg cell expansion by IVIG in patients with autoimmune diseases lack correlation with IL-33. Treg cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to IVIG therapy.
Collapse
Affiliation(s)
- Mohan S Maddur
- Institut National de la Santé et de la Recherche Médicale, Unité 1138, Paris, 75006, France.,Centre de Recherche des Cordeliers, Equipe- Immunopathologie et immuno-intervention thérapeutique, Paris, 75006, France.,Sorbonne Universités, UPMC Univ Paris 06, UMR S 1138, Paris, 75006, France.,Université Paris Descartes, UMR S 1138, Paris, 75006, France.,Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA, 30329, USA
| | - Emmanuel Stephen-Victor
- Institut National de la Santé et de la Recherche Médicale, Unité 1138, Paris, 75006, France.,Centre de Recherche des Cordeliers, Equipe- Immunopathologie et immuno-intervention thérapeutique, Paris, 75006, France.,Sorbonne Universités, UPMC Univ Paris 06, UMR S 1138, Paris, 75006, France
| | - Mrinmoy Das
- Institut National de la Santé et de la Recherche Médicale, Unité 1138, Paris, 75006, France.,Centre de Recherche des Cordeliers, Equipe- Immunopathologie et immuno-intervention thérapeutique, Paris, 75006, France.,Sorbonne Universités, UPMC Univ Paris 06, UMR S 1138, Paris, 75006, France
| | - Praveen Prakhar
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560012, India
| | - Varun K Sharma
- Institut National de la Santé et de la Recherche Médicale, Unité 1138, Paris, 75006, France.,Centre de Recherche des Cordeliers, Equipe- Immunopathologie et immuno-intervention thérapeutique, Paris, 75006, France.,Sorbonne Universités, UPMC Univ Paris 06, UMR S 1138, Paris, 75006, France.,Université Paris Descartes, UMR S 1138, Paris, 75006, France
| | - Vikas Singh
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560012, India
| | - Magalie Rabin
- Sorbonne Universités, UPMC Univ Paris 06, UMR S 1138, Paris, 75006, France
| | - Jamma Trinath
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560012, India
| | - Kithiganahalli N Balaji
- Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560012, India
| | - Francis Bolgert
- Réanimation Neurologique, Neurologie 1, Hôpital de la Pitié-Salpêtrière, Paris, 75651, France
| | - Jean-Michel Vallat
- Centre de Référence 'Neuropathies Périphériques Rares' et Service de Neurologie, Hôpital Universitaire Limoges, Limoges, 87042, France
| | - Laurent Magy
- Centre de Référence 'Neuropathies Périphériques Rares' et Service de Neurologie, Hôpital Universitaire Limoges, Limoges, 87042, France
| | - Srini V Kaveri
- Institut National de la Santé et de la Recherche Médicale, Unité 1138, Paris, 75006, France. .,Centre de Recherche des Cordeliers, Equipe- Immunopathologie et immuno-intervention thérapeutique, Paris, 75006, France. .,Sorbonne Universités, UPMC Univ Paris 06, UMR S 1138, Paris, 75006, France. .,Université Paris Descartes, UMR S 1138, Paris, 75006, France.
| | - Jagadeesh Bayry
- Institut National de la Santé et de la Recherche Médicale, Unité 1138, Paris, 75006, France. .,Centre de Recherche des Cordeliers, Equipe- Immunopathologie et immuno-intervention thérapeutique, Paris, 75006, France. .,Sorbonne Universités, UPMC Univ Paris 06, UMR S 1138, Paris, 75006, France. .,Université Paris Descartes, UMR S 1138, Paris, 75006, France.
| |
Collapse
|
10
|
Bowen JR, Quicke KM, Maddur MS, O’Neal JT, McDonald CE, Fedorova NB, Puri V, Shabman RS, Pulendran B, Suthar MS. Zika Virus Antagonizes Type I Interferon Responses during Infection of Human Dendritic Cells. PLoS Pathog 2017; 13:e1006164. [PMID: 28152048 PMCID: PMC5289613 DOI: 10.1371/journal.ppat.1006164] [Citation(s) in RCA: 196] [Impact Index Per Article: 28.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Accepted: 01/02/2017] [Indexed: 12/13/2022] Open
Abstract
Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that is causally linked to severe neonatal birth defects, including microcephaly, and is associated with Guillain-Barre syndrome in adults. Dendritic cells (DCs) are an important cell type during infection by multiple mosquito-borne flaviviruses, including dengue virus, West Nile virus, Japanese encephalitis virus, and yellow fever virus. Despite this, the interplay between ZIKV and DCs remains poorly defined. Here, we found human DCs supported productive infection by a contemporary Puerto Rican isolate with considerable variability in viral replication, but not viral binding, between DCs from different donors. Historic isolates from Africa and Asia also infected DCs with distinct viral replication kinetics between strains. African lineage viruses displayed more rapid replication kinetics and infection magnitude as compared to Asian lineage viruses, and uniquely induced cell death. Infection of DCs with both contemporary and historic ZIKV isolates led to minimal up-regulation of T cell co-stimulatory and MHC molecules, along with limited secretion of inflammatory cytokines. Inhibition of type I interferon (IFN) protein translation was observed during ZIKV infection, despite strong induction at the RNA transcript level and up-regulation of other host antiviral proteins. Treatment of human DCs with RIG-I agonist potently restricted ZIKV replication, while type I IFN had only modest effects. Mechanistically, we found all strains of ZIKV antagonized type I IFN-mediated phosphorylation of STAT1 and STAT2. Combined, our findings show that ZIKV subverts DC immunogenicity during infection, in part through evasion of type I IFN responses, but that the RLR signaling pathway is still capable of inducing an antiviral state, and therefore may serve as an antiviral therapeutic target.
Collapse
Affiliation(s)
- James R. Bowen
- Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, United States of America
- Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, Georgia, United States of America
| | - Kendra M. Quicke
- Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, United States of America
- Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, Georgia, United States of America
| | - Mohan S. Maddur
- Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, Georgia, United States of America
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America
| | - Justin T. O’Neal
- Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, United States of America
- Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, Georgia, United States of America
| | - Circe E. McDonald
- Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, United States of America
- Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, Georgia, United States of America
| | - Nadia B. Fedorova
- J. Craig Venter Institute, Rockville, Maryland, United States of America
| | - Vinita Puri
- J. Craig Venter Institute, Rockville, Maryland, United States of America
| | - Reed S. Shabman
- J. Craig Venter Institute, Rockville, Maryland, United States of America
| | - Bali Pulendran
- Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, Georgia, United States of America
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America
| | - Mehul S. Suthar
- Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, United States of America
- Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, Georgia, United States of America
| |
Collapse
|
11
|
Maddur MS, Bayry J. B cells drive Th2 responses by instructing human dendritic cell maturation. Oncoimmunology 2015; 4:e1005508. [PMID: 26155405 DOI: 10.1080/2162402x.2015.1005508] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2014] [Accepted: 12/30/2014] [Indexed: 12/12/2022] Open
Abstract
Dendritic cells (DCs) are known to regulate the functions of various immune cells. Reciprocal signaling by these immune cells also "educate" the DCs and determine the quality of the ensuing immune responses. Recently, we demonstrated that human DCs undergo maturation upon interaction with activated B cells to acquire unique abilities to promote polarization of Th2 cells.
Collapse
Affiliation(s)
- Mohan S Maddur
- Institut National de la Santé et de la Recherche Médicale ; Paris, France ; Centre de Recherche des Cordeliers; Equipe - Immunopathology and Therapeutic Immunointervention ; Paris, France ; Sorbonne Universités, UPMC Univ Paris , Paris, France ; Emory Vaccine Center; Yerkes National Primate Research Center; Emory University ; Atlanta, GA, USA
| | - Jagadeesh Bayry
- Institut National de la Santé et de la Recherche Médicale ; Paris, France ; Centre de Recherche des Cordeliers; Equipe - Immunopathology and Therapeutic Immunointervention ; Paris, France ; Sorbonne Universités, UPMC Univ Paris , Paris, France ; Université Paris Descartes ; Sorbonne Paris Cité ; Paris, France ; International Associated Laboratory IMPACT (Institut National de la Santé et de la Recherche Médicale, France - Indian Council of Medical Research, India); National Institute of Immunohematology ; Mumbai, India
| |
Collapse
|
12
|
Maddur MS, Trinath J, Rabin M, Bolgert F, Guy M, Vallat JM, Magy L, Balaji KN, Kaveri SV, Bayry J. Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation. Cell Mol Immunol 2014; 12:650-2. [PMID: 25482074 DOI: 10.1038/cmi.2014.117] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2014] [Revised: 10/30/2014] [Accepted: 10/30/2014] [Indexed: 01/06/2023] Open
Affiliation(s)
- Mohan S Maddur
- Institut National de la Santé et de la Recherche Médicale, Paris, France.,Centre de Recherche des Cordeliers, Equipe - Immunopathology and Therapeutic Immunointervention, Paris, France.,Sorbonne Universités - UPMC Univ Paris 6, Paris, France.,Université Paris Descartes, Paris, France
| | - Jamma Trinath
- Institut National de la Santé et de la Recherche Médicale, Paris, France.,Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India
| | - Magalie Rabin
- Institut National de la Santé et de la Recherche Médicale, Paris, France.,Centre de Recherche des Cordeliers, Equipe - Immunopathology and Therapeutic Immunointervention, Paris, France.,Sorbonne Universités - UPMC Univ Paris 6, Paris, France.,Centre de Référence 'Neuropathies Périphériques Rares' et Service de Neurologie, Hôpital Universitaire Limoges, Limoges, France
| | - Francis Bolgert
- Réanimation Neurologique, Neurologie 1, Hôpital de la Pitié-Salpêtrière, Paris, France
| | - Moneger Guy
- Réanimation Neurologique, Neurologie 1, Hôpital de la Pitié-Salpêtrière, Paris, France
| | - Jean-Michel Vallat
- Centre de Référence 'Neuropathies Périphériques Rares' et Service de Neurologie, Hôpital Universitaire Limoges, Limoges, France
| | - Laurent Magy
- Centre de Référence 'Neuropathies Périphériques Rares' et Service de Neurologie, Hôpital Universitaire Limoges, Limoges, France
| | | | - Srini V Kaveri
- Institut National de la Santé et de la Recherche Médicale, Paris, France.,Centre de Recherche des Cordeliers, Equipe - Immunopathology and Therapeutic Immunointervention, Paris, France.,Sorbonne Universités - UPMC Univ Paris 6, Paris, France.,Université Paris Descartes, Paris, France.,International Associated Laboratory IMPACT (Institut National de la Santé et de la Recherche Médicale, France - Indian Council of Medical Research, India), National Institute of Immunohaematology, Mumbai, India
| | - Jagadeesh Bayry
- Institut National de la Santé et de la Recherche Médicale, Paris, France.,Centre de Recherche des Cordeliers, Equipe - Immunopathology and Therapeutic Immunointervention, Paris, France.,Sorbonne Universités - UPMC Univ Paris 6, Paris, France.,Université Paris Descartes, Paris, France.,International Associated Laboratory IMPACT (Institut National de la Santé et de la Recherche Médicale, France - Indian Council of Medical Research, India), National Institute of Immunohaematology, Mumbai, India
| |
Collapse
|
13
|
Oh JZ, Ravindran R, Chassaing B, Carvalho FA, Maddur MS, Bower M, Hakimpour P, Gill KP, Nakaya HI, Yarovinsky F, Sartor RB, Gewirtz AT, Pulendran B. TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination. Immunity 2014; 41:478-492. [PMID: 25220212 DOI: 10.1016/j.immuni.2014.08.009] [Citation(s) in RCA: 367] [Impact Index Per Article: 36.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2014] [Accepted: 08/06/2014] [Indexed: 11/16/2022]
Abstract
Systems biological analysis of immunity to the trivalent inactivated influenza vaccine (TIV) in humans revealed a correlation between early expression of TLR5 and the magnitude of the antibody response. Vaccination of Trl5(-/-) mice resulted in reduced antibody titers and lower frequencies of plasma cells, demonstrating a role for TLR5 in immunity to TIV. This was due to a failure to sense host microbiota. Thus, antibody responses in germ-free or antibiotic-treated mice were impaired, but restored by oral reconstitution with a flagellated, but not aflagellated, strain of E. coli. TLR5-mediated sensing of flagellin promoted plasma cell differentiation directly and by stimulating lymph node macrophages to produce plasma cell growth factors. Finally, TLR5-mediated sensing of the microbiota also impacted antibody responses to the inactivated polio vaccine, but not to adjuvanted vaccines or the live-attenuated yellow fever vaccine. These results reveal an unappreciated role for gut microbiota in promoting immunity to vaccination.
Collapse
Affiliation(s)
- Jason Z Oh
- Emory Vaccine Center, Emory University, Atlanta, GA 30329, USA; Yerkes National Primate Center, Emory University, Atlanta, GA 30329, USA
| | - Rajesh Ravindran
- Emory Vaccine Center, Emory University, Atlanta, GA 30329, USA; Yerkes National Primate Center, Emory University, Atlanta, GA 30329, USA
| | - Benoit Chassaing
- Center for Inflammation, Immunity, and Infection, Georgia State University, Atlanta, GA 30302, USA
| | - Frederic A Carvalho
- Center for Inflammation, Immunity, and Infection, Georgia State University, Atlanta, GA 30302, USA; INSERM U1107, Universite d'Auvergne, 63001 Clermont-Ferrand Cedex 1, France
| | - Mohan S Maddur
- Emory Vaccine Center, Emory University, Atlanta, GA 30329, USA; Yerkes National Primate Center, Emory University, Atlanta, GA 30329, USA
| | - Maureen Bower
- National Gnotobiotic Rodent Resource Center, University of North Carolina, Chapel Hill, NC 27514, USA
| | - Paul Hakimpour
- Yerkes National Primate Center, Emory University, Atlanta, GA 30329, USA
| | - Kiran P Gill
- Emory Vaccine Center, Emory University, Atlanta, GA 30329, USA; Yerkes National Primate Center, Emory University, Atlanta, GA 30329, USA
| | - Helder I Nakaya
- Department of Pathology, School of Medicine, Emory University, Atlanta, GA 30329, USA; Department of Clinical and Toxicological Analyses, Institute of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil
| | - Felix Yarovinsky
- Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
| | - R Balfour Sartor
- National Gnotobiotic Rodent Resource Center, University of North Carolina, Chapel Hill, NC 27514, USA
| | - Andrew T Gewirtz
- Center for Inflammation, Immunity, and Infection, Georgia State University, Atlanta, GA 30302, USA
| | - Bali Pulendran
- Emory Vaccine Center, Emory University, Atlanta, GA 30329, USA; Yerkes National Primate Center, Emory University, Atlanta, GA 30329, USA; Department of Pathology, School of Medicine, Emory University, Atlanta, GA 30329, USA.
| |
Collapse
|
14
|
Maddur MS, Sharma M, Hegde P, Stephen-Victor E, Pulendran B, Kaveri SV, Bayry J. Human B cells induce dendritic cell maturation and favour Th2 polarization by inducing OX-40 ligand. Nat Commun 2014; 5:4092. [PMID: 24910129 DOI: 10.1038/ncomms5092] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2013] [Accepted: 05/09/2014] [Indexed: 01/08/2023] Open
Abstract
Dendritic cells (DCs) play a critical role in immune homeostasis by regulating the functions of various immune cells, including T and B cells. Notably, DCs also undergo education on reciprocal signalling by these immune cells and environmental factors. Various reports demonstrated that B cells have profound regulatory functions, although only few reports have explored the regulation of human DCs by B cells. Here we demonstrate that activated but not resting B cells induce maturation of DCs with distinct features to polarize Th2 cells that secrete interleukin (IL)-5, IL-4 and IL-13. B-cell-induced maturation of DCs is contact dependent and implicates signalling of B-cell activation molecules CD69, B-cell-activating factor receptor, and transmembrane activator and calcium-modulating cyclophilin ligand interactor. Mechanistically, differentiation of Th2 cells by B-cell-matured DCs is dependent on OX-40 ligand. Collectively, our results suggest that B cells have the ability to control their own effector functions by enhancing the ability of human DCs to mediate Th2 differentiation.
Collapse
Affiliation(s)
- Mohan S Maddur
- 1] Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris F-75006, France [2] Centre de Recherche des Cordeliers, Equipe 16- Immunopathology and Therapeutic Immunointervention, Université Pierre et Marie Curie - Paris 6, UMR S 1138, 15 rue de l'Ecole de Médicine, Paris F-75006, France [3] Université Paris Descartes, UMR S 1138, Paris F-75006, France [4] Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, Georgia 30329, USA
| | - Meenu Sharma
- 1] Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris F-75006, France [2] Université de Technologie de Compiègne, Compiègne F-60205, France
| | - Pushpa Hegde
- 1] Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris F-75006, France [2] Université de Technologie de Compiègne, Compiègne F-60205, France
| | - Emmanuel Stephen-Victor
- 1] Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris F-75006, France [2] Centre de Recherche des Cordeliers, Equipe 16- Immunopathology and Therapeutic Immunointervention, Université Pierre et Marie Curie - Paris 6, UMR S 1138, 15 rue de l'Ecole de Médicine, Paris F-75006, France
| | - Bali Pulendran
- Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, Georgia 30329, USA
| | - Srini V Kaveri
- 1] Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris F-75006, France [2] Centre de Recherche des Cordeliers, Equipe 16- Immunopathology and Therapeutic Immunointervention, Université Pierre et Marie Curie - Paris 6, UMR S 1138, 15 rue de l'Ecole de Médicine, Paris F-75006, France [3] Université Paris Descartes, UMR S 1138, Paris F-75006, France [4] International Associated Laboratory IMPACT (Institut National de la Santé et de la Recherche Médicale, France - Indian Council of Medical Research, India), National Institute of Immunohaematology, Mumbai 400012, India
| | - Jagadeesh Bayry
- 1] Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris F-75006, France [2] Centre de Recherche des Cordeliers, Equipe 16- Immunopathology and Therapeutic Immunointervention, Université Pierre et Marie Curie - Paris 6, UMR S 1138, 15 rue de l'Ecole de Médicine, Paris F-75006, France [3] Université Paris Descartes, UMR S 1138, Paris F-75006, France [4] International Associated Laboratory IMPACT (Institut National de la Santé et de la Recherche Médicale, France - Indian Council of Medical Research, India), National Institute of Immunohaematology, Mumbai 400012, India
| |
Collapse
|
15
|
Ravindran R, Khan N, Nakaya HI, Li S, Loebbermann J, Maddur MS, Park Y, Jones DP, Chappert P, Davoust J, Weiss DS, Virgin HW, Ron D, Pulendran B. Vaccine activation of the nutrient sensor GCN2 in dendritic cells enhances antigen presentation. Science 2013; 343:313-317. [PMID: 24310610 DOI: 10.1126/science.1246829] [Citation(s) in RCA: 158] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
The yellow fever vaccine YF-17D is one of the most successful vaccines ever developed in humans. Despite its efficacy and widespread use in more than 600 million people, the mechanisms by which it stimulates protective immunity remain poorly understood. Recent studies using systems biology approaches in humans have revealed that YF-17D-induced early expression of general control nonderepressible 2 kinase (GCN2) in the blood strongly correlates with the magnitude of the later CD8(+) T cell response. We demonstrate a key role for virus-induced GCN2 activation in programming dendritic cells to initiate autophagy and enhanced antigen presentation to both CD4(+) and CD8(+) T cells. These results reveal an unappreciated link between virus-induced integrated stress response in dendritic cells and the adaptive immune response.
Collapse
Affiliation(s)
- Rajesh Ravindran
- Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30329, USA
| | - Nooruddin Khan
- Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30329, USA.,Department of Biotechnology, School of Life Sciences, University of Hyderabad, Hyderabad 500046, India
| | - Helder I Nakaya
- Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30329, USA.,Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA
| | - Shuzhao Li
- Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30329, USA
| | - Jens Loebbermann
- Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30329, USA
| | - Mohan S Maddur
- Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30329, USA
| | - Youngja Park
- College of Pharmacy, Korea University, 339-700 Korea
| | - Dean P Jones
- Department of Medicine, Division of Pulmonary, Allergy and Critical Care, Emory University, Atlanta, GA 30322, USA
| | - Pascal Chappert
- Institut National de la Santéet de la Recherche Médicale U1013, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris 75743 Paris Cedex 15, France
| | - Jean Davoust
- Institut National de la Santéet de la Recherche Médicale U1013, Paris, France.,Université Paris Descartes, Sorbonne Paris Cité, Paris 75743 Paris Cedex 15, France
| | - David S Weiss
- Department of Medicine, Division of Infectious Diseases, Emory University, Atlanta, GA 30329, USA
| | - Herbert W Virgin
- Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
| | - David Ron
- University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, UK
| | - Bali Pulendran
- Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, 954 Gatewood Road, Atlanta, GA 30329, USA.,Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA
| |
Collapse
|
16
|
Maddur MS, Kaveri SV, Bayry J. Dual role of CpG-stimulated B cells in the regulation of dendritic cells: comment on the article by Berggren et al. ACTA ACUST UNITED AC 2013; 65:2215-6. [PMID: 23666620 DOI: 10.1002/art.38004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
17
|
Othy S, Hegde P, Topçu S, Sharma M, Maddur MS, Lacroix-Desmazes S, Bayry J, Kaveri SV. Intravenous Gammaglobulin Inhibits Encephalitogenic Potential of Pathogenic T Cells and Interferes with their Trafficking to the Central Nervous System, Implicating Sphingosine-1 Phosphate Receptor 1–Mammalian Target of Rapamycin Axis. J I 2013; 190:4535-41. [DOI: 10.4049/jimmunol.1201965] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
18
|
Maddur MS, Sharma M, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J. Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations. J Clin Immunol 2012; 33 Suppl 1:S62-6. [PMID: 22864643 DOI: 10.1007/s10875-012-9752-6] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2012] [Accepted: 07/24/2012] [Indexed: 12/27/2022]
Abstract
PURPOSE Th17 cells and their cytokines play a critical role in the pathogenesis of various autoimmune and inflammatory diseases. Recently, we have demonstrated that intravenous immunoglobulin (IVIG) suppresses differentiation, amplification, and functions of human Th17 cells. In this report we investigated whether IVIG inhibits IL-17 production by Th17 cells cultured in the presence of IL-23 and whether the inhibitory effect of IVIG on IL-17 production implicates anti-IL-17 antibodies. METHODS Naive CD4(+) T cells were stimulated in the presence of TGF-β, IL-21, and IL-23 for the differentiation of Th17 cells. Memory CD4(+) T cells were stimulated with IL-1β, IL-6, and IL-23 for the amplification of Th17 cells. IVIG (0.15 mM) was added to the cells 12 h after initiation of cultures. IL-17A cytokine and anti-IL-17 antibodies were measured by ELISA. RESULTS IL-23 did not deter the inhibitory effect of IVIG on IL-17 production from the differentiating and expanding Th17 cells. Further, suppression of IL-17 by IVIG did not implicate anti-IL-17 antibodies in the immunoglobulin preparations. CONCLUSION The effect of IVIG on the inhibition of IL-17 production by Th17 cells is a consequence of modulation of Th17 cells and their intracellular signaling pathways and not due to passive neutralization of IL-17 by anti-IL-17 antibodies in the immunoglobulin preparations.
Collapse
Affiliation(s)
- Mohan S Maddur
- Institut National de la Santé et de la Recherche Médicale, Unité 872, 15 rue de l'Ecole de Médicine, Paris 75006, France
| | | | | | | | | | | |
Collapse
|
19
|
Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012; 181:8-18. [PMID: 22640807 DOI: 10.1016/j.ajpath.2012.03.044] [Citation(s) in RCA: 420] [Impact Index Per Article: 35.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/16/2011] [Revised: 02/07/2012] [Accepted: 03/15/2012] [Indexed: 12/22/2022]
Abstract
Th17 cells that secrete the cytokines IL-17A and IL-17F and express lineage-specific transcription factor RORC (RORγt in mice) represent a distinct lineage of CD4(+) T cells. Transforming growth factor-β and inflammatory cytokines, such as IL-6, IL-21, IL-1β, and IL-23, play central roles in the generation of Th17 cells. Th17 cells are critical for the clearance of extracellular pathogens, including Candida and Klebsiella. However, under certain conditions, these cells and their effector molecules, such as IL-17, IL-21, IL-22, GM-CSF, and CCL20, are associated with the pathogenesis of several autoimmune and inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, inflammatory bowel disease, and allergy and asthma. This review discusses these disease states and the various therapeutic strategies under investigation to target Th17 cells, which include blocking the differentiation and amplification of Th17 cells, inhibiting or neutralizing the cytokines of Th17 cells, and suppressing the transcription factors specific for Th17 cells.
Collapse
|
20
|
Trinath J, Maddur MS, Kaveri SV, Balaji KN, Bayry J. Mycobacterium tuberculosis Promotes Regulatory T-Cell Expansion via Induction of Programmed Death-1 Ligand 1 (PD-L1, CD274) on Dendritic Cells. J Infect Dis 2012; 205:694-6. [DOI: 10.1093/infdis/jir820] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
|
21
|
Hegde P, Maddur MS, Friboulet A, Bayry J, Kaveri SV. Viscum album exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2. PLoS One 2011; 6:e26312. [PMID: 22028854 PMCID: PMC3196571 DOI: 10.1371/journal.pone.0026312] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2011] [Accepted: 09/23/2011] [Indexed: 12/18/2022] Open
Abstract
Viscum album (VA) preparations are extensively used as complementary therapy in cancer and are shown to exert anti-tumor activities which involve the cytotoxic properties, induction of apoptosis, inhibition of angiogenesis and several other immunomodulatory mechanisms. In addition to their application in cancer therapy, VA preparations have also been successfully utilized in the treatment of several inflammatory pathologies. Owing to the intricate association of inflammation and cancer and in view of the fact that several anti-tumor phytotherapeutics also exert a potent anti-inflammatory effect, we hypothesized that VA exerts an anti-inflammatory effect that is responsible for its therapeutic benefit. Since, inflammatory cytokine-induced cyclo-oxygenase-2 (COX-2) and prostaglandin E2 (PGE2) play a critical role in the pathogenesis of inflammatory diseases, we investigated the anti-inflammatory effect of VA on regulation of cyclo-oxygenase expression and PGE2 biosynthesis by using human lung adenocarcinoma cells (A549 cells) as a model. A549 cells were stimulated with IL-1β and treated with VA preparation (VA Qu Spez) for 18 hours. PGE2 was analysed in the culture supernatants by enzyme immunoassay. Expression of COX-2 and COX-1 proteins was analyzed by immunoblotting and the expression of COX-2 mRNA was assessed by semi-quantitative RT-PCR. We found that VA Qu Spez inhibit the secretion of IL-1β-induced PGE2 in a dose-dependent manner. Further, we also show that this inhibitory action was associated with a reduced expression of COX-2 without modulating the COX-1 expression. Together these results demonstrate a novel anti-inflammatory mechanism of action of VA preparations wherein VA exerts an anti-inflammatory effect by inhibiting cytokine-induced PGE2 via selective inhibition of COX-2.
Collapse
Affiliation(s)
- Pushpa Hegde
- Institut National de la Santé et de la Recherche Médicale, Unité 872, Paris, France
- Université de Technologie de Compiègne, Compiègne, France
| | - Mohan S. Maddur
- Institut National de la Santé et de la Recherche Médicale, Unité 872, Paris, France
- Centre de Recherche des Cordeliers, Equipe 16- Immunopathology and Therapeutic Immunointervention, Université Pierre et Marie Curie – Paris 6, UMR S 872, Paris, France
- Université Paris Descartes, UMR S 872, Paris, France
| | - Alain Friboulet
- Université de Technologie de Compiègne, UMR CNRS 6022, Compiègne, France
| | - Jagadeesh Bayry
- Institut National de la Santé et de la Recherche Médicale, Unité 872, Paris, France
- Centre de Recherche des Cordeliers, Equipe 16- Immunopathology and Therapeutic Immunointervention, Université Pierre et Marie Curie – Paris 6, UMR S 872, Paris, France
- Université Paris Descartes, UMR S 872, Paris, France
| | - Srini V. Kaveri
- Institut National de la Santé et de la Recherche Médicale, Unité 872, Paris, France
- Centre de Recherche des Cordeliers, Equipe 16- Immunopathology and Therapeutic Immunointervention, Université Pierre et Marie Curie – Paris 6, UMR S 872, Paris, France
- Université Paris Descartes, UMR S 872, Paris, France
- * E-mail:
| |
Collapse
|
22
|
Abstract
Intravenous immunoglobulin (IVIg) can exert beneficial effects in autoimmune and inflammatory diseases via several mutually non-exclusive mechanisms. While, IVIg can directly modulate the functions of both innate and adaptive immune cells such as dendritic cells (DC), macrophages, B and T cells, several reports have also highlighted that the regulation of immune responses by IVIg can be indirect. In view of these results, we aimed at exploring whether indirect regulation of immune cells by 'IVIg-educated' innate cells is a universal phenomenon. We addressed this question by deciphering the modulation of B cell functions by 'IVIg-educated' DC. Our results indicate that human B cells are resistant to immunomodulation by 'IVIg-educated' DC. However, IVIg at therapeutic concentrations can directly inhibit B cell activation and proliferation. These results thus suggest that, indirect modulation of immune cells by IVIg is not a universal phenomenon.
Collapse
Affiliation(s)
- Mohan S Maddur
- Institut National de la Santé et de la Recherche Médicale, Unité 872, 15 rue de l'Ecole de Médicine, Paris, France
| | | | | | | | | |
Collapse
|
23
|
Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol 2011; 164 Suppl 2:2-5. [PMID: 21466545 DOI: 10.1111/j.1365-2249.2011.04387.x] [Citation(s) in RCA: 93] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Intravenous immunoglobulin (IVIG) is a therapeutic compound prepared from pools of plasma obtained from several thousand healthy blood donors. For more than 20 years, IVIG has been used in the treatment of a wide range of primary and secondary immunodeficiencies. IVIG now represents a standard therapeutic option for most antibody deficiencies. Routinely, IVIG is used in patients with X-linked agammaglobulinaemia (XLA), common variable immunodeficiency (CVID), X-linked hyper-IgM, severe combined immunodeficiency, Wiskott-Aldrich syndrome, and selective IgG class deficiency. In addition, IVIG is used extensively in the treatment of a wide variety of autoimmune disorders. IVIG is administered at distinct doses in the two clinical settings: whereas immunodeficient patients are treated with replacement levels of IVIG, patients with autoimmune and inflammatory diseases are administered with very high doses of IVIG. Several lines of experimental evidence gathered in the recent years suggest that the therapeutic beneficial effect of IVIG in immunodeficiencies reflects an active role for IVIG, rather than a mere passive transfer of antibodies.
Collapse
Affiliation(s)
- S V Kaveri
- Institut National de la Santé et de la Recherche Médicale Unité 872, Paris, France.
| | | | | | | | | |
Collapse
|
24
|
Maddur MS, Vani J, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol 2011; 127:823-30.e1-7. [DOI: 10.1016/j.jaci.2010.12.1102] [Citation(s) in RCA: 122] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2010] [Revised: 12/17/2010] [Accepted: 12/27/2010] [Indexed: 11/28/2022]
|
25
|
Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Sibéril S, Dimitrov JD, Lacroix-Desmazes S, Berdah M, Crabol Y, Oksenhendler E, Lévy Y, Mouthon L, Sautès-Fridman C, Hermine O, Kaveri SV. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun 2010; 36:9-15. [PMID: 20970960 DOI: 10.1016/j.jaut.2010.09.006] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2010] [Revised: 09/20/2010] [Accepted: 09/23/2010] [Indexed: 12/28/2022]
Abstract
Common variable immunodeficiency (CVID) is associated with low serum immunoglobulin concentrations and an increased susceptibility to infections and autoimmune diseases. The treatment of choice for CVID patients is replacement intravenous immunoglobulin (IVIg) therapy. IVIg has been beneficial in preventing or alleviating the severity of infections and autoimmune and inflammatory process in majority of CVID patients. Although the mechanisms of action of IVIg given as 'therapeutic high dose' in patients with autoimmune diseases are well studied, the underlying mechanisms of beneficial effects of IVIg in primary immunodeficiencies are not completely understood. Therefore we investigated the effect of 'replacement dose' of IVIg by probing its action on B cells from CVID patients. We demonstrate that IVIg at low doses induces proliferation and immunoglobulin synthesis from B cells of CVID patients. Interestingly, B cell stimulation by IVIg is not associated with induction of B cell effector cytokine IFN-γ and of transcription factor T-bet. Together, our results indicate that in some CVID patients, IVIg rectifies the defective signaling of B cells normally provided by T cells and delivers T-independent signaling for B cells to proliferate. IVIg 'replacement therapy' in primary immunodeficiencies is therefore not a merepassive transfer of antibodies to prevent exclusively the recurrent infections; rather it has an active role in regulating autoimmune and inflammatory responses through modulating B cell functions and thus imposing dynamic equilibrium of the immune system.
Collapse
Affiliation(s)
- Jagadeesh Bayry
- Institut National de la Santé et de la Recherche Médicale Unité 872, F-75006 Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Maddur MS, Kaveri SV, Bayry J. World Rabies Day: a prime role for veterinarians in rabies control. Nat Rev Microbiol 2010; 9:75. [PMID: 21102486 DOI: 10.1038/nrmicro2451-c1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
27
|
Maddur MS, Kishore S, Chockalingam AK, Gopalakrishna S, Singh N, Suryanarayana VV, Gajendragad MR. The relationship between cellular immune response to foot-and-mouth disease virus Asia 1 and viral persistence in Indian cattle (Bos indicus). Res Vet Sci 2010; 89:36-40. [DOI: 10.1016/j.rvsc.2010.01.018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2009] [Revised: 01/13/2010] [Accepted: 01/28/2010] [Indexed: 10/19/2022]
|
28
|
Maddur MS, Vani J, Lacroix-Desmazes S, Kaveri SV, Bayry J. Contribution of myeloid dendritic cells to type I interferon-induced cytokines and chemokines: comment on the article by Bilgic et al. ACTA ACUST UNITED AC 2010; 62:2181-2; author reply 2182. [PMID: 20506372 DOI: 10.1002/art.27494] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
29
|
|
30
|
|
31
|
Maddur MS, Kaveri SV, Bayry J. Basophils as antigen presenting cells. Trends Immunol 2010; 31:45-8. [PMID: 20060781 DOI: 10.1016/j.it.2009.12.004] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2009] [Revised: 12/11/2009] [Accepted: 12/14/2009] [Indexed: 02/04/2023]
Abstract
Recent reports demonstrate that basophils act as antigen presenting cells to drive Th2 and IgE responses against protease and protein allergens and helminth parasites. Through MHC class II-dependent cognate interactions with CD4(+) T cells in the context of co-stimulatory molecules, and through secretion of IL-4, IL-13 and thymic stromal lymphopoietin, basophils drive antigen-specific Th2 responses. These results have uncovered previously unknown functions of basophils, and should aid in designing novel therapeutic strategies for asthma and allergic conditions.
Collapse
|
32
|
Maddur MS, Gajendragad MR, Gopalakrishna S, Singh N. Erratum to: Comparative study of experimental foot-and-mouth disease in cattle (Bos indicus) and buffaloes (Bubalus bubalis). Vet Res Commun 2009. [DOI: 10.1007/s11259-009-9328-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
Hegde NR, Maddur MS, Rao PP, Kaveri SV, Bayry J. Thermostable foot-and-mouth disease virus as a vaccine candidate for endemic countries: A perspective. Vaccine 2009; 27:2199-201. [DOI: 10.1016/j.vaccine.2009.01.032] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2009] [Accepted: 01/12/2009] [Indexed: 11/29/2022]
|
34
|
Maddur MS, Gajendragad MR, Kishore S, Gopalakrishna S, Singh N. Kinetics of immune response to foot-and-mouth disease virus (type Asia 1) in experimental cattle. Vet Res Commun 2009. [DOI: 10.1007/s11259-009-9208-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
35
|
Maddur MS, Mohan MS, Gajendragad MR, Kishore S, Gopalakrishna S, Singh N. Kinetics of immune response to foot-and-mouth disease virus (type Asia 1) in experimental cattle. Vet Res Commun 2008; 33:103-9. [PMID: 18648998 DOI: 10.1007/s11259-008-9076-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/26/2008] [Indexed: 11/28/2022]
Abstract
Humoral and mucosal (secretory antibody)immune response to FMDV type Asia 1 in cattle was analyzed after vaccination and infection using virus neutralizing test (VNT). Vaccination (1/16th the usual dose) failed to protect cattle from generalized clinical disease following experimental FMDV Asia 1 infection. Our results showed that infection induced higher and prolonged serum antibody titres indicating antigen mass is important for optimal immune response. Experimental FMDV infection induced significant secretory antibody (mucosal) response in cattle. Though, there was no difference in the serum antibody response between the cattle that developed generalized infection (unprotected) and those with only localized infection (protected), secretory antibody response differed, wherein the unprotected cattle had higher secretory response than protected cattle. Thus, FMDV Asia 1 infection stimulates a similar serum antibody response and a unique secretory antibody response among the infected cattle.
Collapse
Affiliation(s)
- Mohan S Maddur
- Indian Veterinary Research Institute, Bangalore, Karnataka, India
| | | | | | | | | | | |
Collapse
|
36
|
Maddur MS, Mohan MS, Gajendragad MR, Kishore S, Chockalingam AK, Suryanarayana VVS, Gopalakrishna S, Singh N. Enhanced mucosal immune response in cattle persistently infected with foot-and-mouth disease virus. Vet Immunol Immunopathol 2008; 125:337-43. [PMID: 18656268 DOI: 10.1016/j.vetimm.2008.05.031] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2007] [Revised: 01/26/2008] [Accepted: 05/30/2008] [Indexed: 11/28/2022]
Abstract
The mucosal immune response to foot-and-mouth disease virus (FMDV) type Asia 1 was examined in experimentally infected cattle by assaying antibodies by the virus-neutralizing test (VNT) and IgA ELISA in two secretory fluids, oesophageal pharyngeal fluid (OPF) and oro-nasal fluid (ONF). Out of 17 animals infected by the intradermo-lingual route, 12 became persistently infected (carriers), as defined by positive antigen capture RT-PCR reactions for FMDV RNA in OPF samples collected at 28 days or later after exposure. This proportion of carriers (71%) with FMDV Asia 1 is comparable to other serotypes of the virus. When the two groups were examined, the carriers and non-carriers showed no difference in the serum antibody titre until the end of the experiment at 182 days post-infection (DPI). However, despite an initial similarity significantly higher neutralizing antibody titres and FMDV-specific IgA response were detected among the carriers than the non-carriers in both of the secretory fluids. The response was higher and more stable in ONF compared to OPF. Thus, mucosal antibody assays have the potential to be used as a means of differentiating carrier from non-carrier cattle. Furthermore, the findings are consistent with the higher mucosal antibody response in carriers being an effect of persistent infection rather than the cause.
Collapse
Affiliation(s)
- Mohan S Maddur
- Indian Veterinary Research Institute, Bangalore, Karnataka, India
| | | | | | | | | | | | | | | |
Collapse
|